Tarsus Pharmaceuticals (TARS) Shares Outstanding (Weighted Average) (2019 - 2026)

Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $43.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 9.18% year-over-year to $43.0 million; the TTM figure through Mar 2026 stood at $43.0 million (up 9.18% YoY), while the FY2025 annual figure was $41.8 million, up 11.11% from the prior year.
• Shares Outstanding (Weighted Average) was $43.0 million for Q1 2026 at Tarsus Pharmaceuticals, up from $41.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $43.0 million in Q1 2026 to a low of $20.7 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $32.9 million across 5 years, with a median of $35.3 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) advanced 1.84% in 2022, then jumped 36.41% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $24.6 million in 2022, then grew by 19.35% to $29.4 million in 2023, then rose by 27.98% to $37.6 million in 2024, then rose by 11.11% to $41.8 million in 2025, then climbed by 2.81% to $43.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $43.0 million (Q1 2026), $41.8 million (Q4 2025), and $41.5 million (Q3 2025), per Business Quant data.